Amicus Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $11.4
- Today's High:
- $12.195
- Open Price:
- $11.48
- 52W Low:
- $7.78
- 52W High:
- $13.84
- Prev. Close:
- $11.39
- Volume:
- 2366665
Company Statistics
- Market Cap.:
- $3.20 billion
- Book Value:
- 0.362
- Revenue TTM:
- $336.79 million
- Operating Margin TTM:
- -51.04%
- Gross Profit TTM:
- $290.63 million
- Profit Margin:
- -60.64%
- Return on Assets TTM:
- -14.07%
- Return on Equity TTM:
- -119.72%
Company Profile
Amicus Therapeutics Inc had its IPO on 2007-05-31 under the ticker symbol FOLD.
The company operates in the Healthcare sector and Biotechnology industry. Amicus Therapeutics Inc has a staff strength of 484 employees.
Stock update
Shares of Amicus Therapeutics Inc opened at $11.48 at the start of the last trading session i.e. 2023-06-02.
The stocks traded within a range of $11.4 - $12.2, and closed at $12.17.
This is a +6.85% increase from the previous day's closing price.
A total volume of 2,366,665 shares were traded at the close of the day’s session.
In the last one week, shares of Amicus Therapeutics Inc have increased by +3.93%.
Amicus Therapeutics Inc's Key Ratios
Amicus Therapeutics Inc has a market cap of $3.20 billion, indicating a price to book ratio of 24.7746 and a price to sales ratio of 10.5064.
In the last 12-months Amicus Therapeutics Inc’s revenue was $336.79 million with a gross profit of $290.63 million and an EBITDA of $-166712000. The EBITDA ratio measures Amicus Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Amicus Therapeutics Inc’s operating margin was -51.04% while its return on assets stood at -14.07% with a return of equity of -119.72%.
In Q1, Amicus Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 9.6%.
Amicus Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- -0.18
Its diluted EPS in the last 12-months stands at $-0.7 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of -0.18. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Amicus Therapeutics Inc’s profitability.
Amicus Therapeutics Inc stock is trading at a EV to sales ratio of 10.4563 and a EV to EBITDA ratio of -15.9064. Its price to sales ratio in the trailing 12-months stood at 10.5064.
Amicus Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $700.52 million
- Total Liabilities
- $138.39 million
- Operating Cash Flow
- $36.26 million
- Capital Expenditure
- $1.94 million
- Dividend Payout Ratio
- 0%
Amicus Therapeutics Inc ended 2023 with $700.52 million in total assets and $0 in total liabilities. Its intangible assets were valued at $700.52 million while shareholder equity stood at $102.57 million.
Amicus Therapeutics Inc ended 2023 with $5.91 million in deferred long-term liabilities, $138.39 million in other current liabilities, 2820000.00 in common stock, $-2585422000.00 in retained earnings and $197.80 million in goodwill. Its cash balance stood at $160.60 million and cash and short-term investments were $267.11 million. The company’s total short-term debt was $8,005,000 while long-term debt stood at $392.66 million.
Amicus Therapeutics Inc’s total current assets stands at $399.70 million while long-term investments were $0 and short-term investments were $106.51 million. Its net receivables were $68.18 million compared to accounts payable of $24.97 million and inventory worth $27.00 million.
In 2023, Amicus Therapeutics Inc's operating cash flow was $36.26 million while its capital expenditure stood at $1.94 million.
Comparatively, Amicus Therapeutics Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- $12.17
- 52-Week High
- $13.84
- 52-Week Low
- $7.78
- Analyst Target Price
- $15.8
Amicus Therapeutics Inc stock is currently trading at $12.17 per share. It touched a 52-week high of $13.84 and a 52-week low of $13.84. Analysts tracking the stock have a 12-month average target price of $15.8.
Its 50-day moving average was $11.46 and 200-day moving average was $11.63 The short ratio stood at 7.99 indicating a short percent outstanding of 0%.
Around 86.1% of the company’s stock are held by insiders while 10576.8% are held by institutions.
Frequently Asked Questions About Amicus Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. The company also develops AT-GAA, a novel treatment paradigm for Pompe disease; and enzyme replacement therapies for Pompe diseases. It has collaboration and license agreements with Nationwide Children’s Hospital; University of Pennsylvania; and GlaxoSmithKline. The company was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.